IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Zacks News
IDEXX (IDXX) Earnings Beat Estimates in Q3, Margins Rise
by Zacks Equity Research
IDEXX (IDXX) registered strong contribution from its CAG business in the third quarter despite pandemic-induced challenges.
Idexx Laboratories (IDXX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 19.01% and 7.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Can Diagnostics Aid Hologic (HOLX) Q4 Sales Amid Coronavirus?
by Zacks Equity Research
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the fourth quarter of fiscal 2020 amid the coronavirus-led economic doldrums.
Owens & Minor (OMI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Owens & Minor's (OMI) PPE sales are likely to have maintained its momentum during Q3, thus driving the top line.
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Within Life Sciences, STERIS (STE) might have registered benefit from pharma customers on growing vaccines and biologics businesses in Q2.
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) third-quarter results benefit from solid segmental performance.
Quidel (QDEL) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Quidel's (QDEL) fiscal third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.
Medical Products' Oct 29 Earnings Roster: SYK, BAX & More
by Trina Mukherjee
Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Varian's (VAR) receipt of 10 Ethos orders in Q4 instills optimism
Why IDEXX Laboratories (IDXX) Might Surprise This Earnings Season
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q3.
LabCorp (LH) Q3 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
LabCorp (LH) Diagnostics business in Q3 grows significantly on organic volume improvements as a result of growing demand for COVID-19 testing.
ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results
Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.
Ecolab (ECL) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Although Ecolab's (ECL) third-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.
NextGen Healthcare (NXGN) Gains 8.1% Post Q2 Earnings Beat
by Zacks Equity Research
NextGen (NXGN) benefited from both its operating segments in Q2.
Top Research Reports for AMD, Workday & Moody's
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Advanced Micro Devices (AMD), Workday (WDAY) and Moody's (MCO).
What's in Store for IDEXX Laboratories (IDXX) in Q3 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) third-quarter top line is likely to have benefited from strength in CAG and LPD businesses.
Illumina (ILMN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its third-quarter sequencing consumable revenue growth.
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Bio-Rad (BIO) Q3 earnings are expected to have benefited from strong sales particularly within core PCR products, Droplet Digital PCR and Process Media.
Boston Scientific (BSX) Q3 Earnings to Grow on Vital Procedures
by Zacks Equity Research
Boston Scientific's (BSX) Q3 sales are expected to have benefited from growing demand for less-deferrable procedures across most of the segments.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics' (DGX) Q3 Earnings Beat, Base Volume Rises
by Zacks Equity Research
In Q3, Quest Diagnostics (DGX) sees strong signs of the health care system returning to pre-pandemic levels